Preclinical Changes in Immunoreactivity and Cellular Architecture during the Progressive Development of Intracranial Neoplasms and an Immunotherapeutic Schedule with a Novel Biological Response Modifier, the T11TS / S-LFA3.

Among neoplasms, brain tumors are particularly " difficult to treat" because of the partial immune privileged status of the brain and the presence of the blood brain barrier (Selmaj, 1996). Many details of progressive development of brain tumors remain unexplored and elucidation of consequent changes of the immune system with correlated cellular architecture and cell kinetics were the major objectives of the present course of investigations. Our studies have indicated that the primary resistance by the immune system to a growing tumor declines after a certain point, resulting in an immune suppressed state in a tumor bearing individual.